Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy
Etxeberria I (1,2,3), Teijeira A (1,2,3), Montuenga LM (2,3,4), Berraondo P (1,2,3), Melero I (5,2,3,6).
(1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
(4) Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(5) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(6) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
Magazine: Cancer Discovery
Date: Jul 3, 2018Immunology [SP]
Cancer genetic alterations and epigenetics control the malignant phenotype of tumor cells and the stroma.
Synergistic oncogenic alterations may cooperatively dictate immunogenicity, level of infiltration by immune system cells, and response to immunotherapy in an epistatic fashion.
The work of Skoulidis and colleagues shows that concomitant RAS and STK11/LKB1 mutations in non-small cell lung adenocarcinomas result in primary resistance to PD-1-based immunotherapy and poor T-cell infiltration. Cancer Discov; 8(7); 794-6. ©2018 AACRSee related article by Skoulidis et al., p. 822.
CITATION Cancer Discov. 2018 Jul;8(7):794-796. doi: 10.1158/2159-8290.CD-18-0573
you mayBE INTERESTED
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.